Leucine-rich repeat kinase 2 (LRRK2) inhibitors
US11958865B1 · kind B1 · utility
0Cited by
1References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 14, 2023 |
| Grant date | Apr 16, 2024 |
| Priority date | — |
| Expiry date | Sep 14, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/05
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to compounds of formula IIaThese compounds are considered useful for the treatment of diseases associated with leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease. Furthermore, the invention relates to pharmaceutical compositions comprising said compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.